Charles River Laboratories International (CRL) P/E ratio
Charles River Laboratories International (CRL) trades at 361.0× its earnings per share over the last twelve months. At the end of fiscal 2023 (December 31, 2023) its P/E ratio was 25.6×. That is 11.5% higher than the 23.0× of fiscal 2022. Figures as of 18 Nov 2026, 06:44 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio today
- 361.0×
- P/E ratio, fiscal 2023
- 25.6×
- Change on fiscal 2022
- +11.5%
- Highest on record
- 49.6×fiscal 2021
- Lowest on record
- 12.8×fiscal 2011
- Fiscal years on record
- 142009–2023
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Charles River Laboratories International P/E ratio, in more detail
Today's figure is 1308.1% above the fiscal 2023 year-end.
Across the 14 fiscal year-ends on record (2009–2023), the highest was 49.6× in fiscal 2021 and the lowest 12.8× in fiscal 2011. Today's P/E ratio is above every one of the 14 fiscal year-ends on record; their median is 24.8×.
P/E ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Charles River Laboratories International P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| Today | 361.0× | — | $332.16 | — | |
| 2025 | — | — | $199.48 | -$2.91 | |
| 2024 | — | — | $184.60 | $0.20 | |
| 2023 | 25.6× | 11.5% up | $236.40 | $9.22 | |
| 2022 | 23.0× | 53.6% down | $217.90 | $9.48 | |
| 2021 | 49.6× | 42.9% up | $376.78 | $7.60 | |
| 2020 | 34.7× | 15.2% up | $249.86 | $7.20 | |
| 2019 | 30.1× | 23.0% up | $152.76 | $5.07 | |
| 2018 | 24.5× | 43.1% down | $113.18 | $4.62 | |
| 2017 | 43.1× | 82.7% up | $109.45 | $2.54 | |
| 2016 | 23.6× | 8.2% down | $76.19 | $3.23 | |
| 2015 | 25.7× | 7.4% up | $80.39 | $3.13 | |
| 2014 | 23.9× | 4.4% down | $63.64 | $2.66 | |
| 2013 | 25.0× | 34.2% up | $53.04 | $2.12 | |
| 2012 | 18.6× | 46.0% up | $37.47 | $2.01 | |
| 2011 | 12.8× | — | $27.33 | $2.14 | |
| 2010 | — | — | $35.54 | -$5.38 | |
| 2009 | 19.4× | — | $33.69 | $1.74 | |
| 2008 | — | — | $26.20 | -$7.80 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
P/E ratio at health care companies of similar size
| Company | P/E ratio |
|---|---|
| Medpace Holdings MEDP | 36.3× |
| Revvity RVTY | 65.7× |
| Exelixis EXEL | 20.5× |
| Charles River Laboratories International CRL | 361.0× |
| Neurocrine Biosciences NBIX | 24.6× |
| Ascendis Pharma ASND | 17.9× |
Price over the last twelve months' earnings per share, as the market data feed reports it.
Charles River Laboratories International, figure by figure
- Charles River Laboratories International market cap
- Charles River Laboratories International revenue
- Charles River Laboratories International earnings
- Charles River Laboratories International earnings per share (EPS)
- Charles River Laboratories International P/S ratio
- Charles River Laboratories International P/B ratio
- Charles River Laboratories International free cash flow
- Charles River Laboratories International operating margin
- Charles River Laboratories International dividend
- Charles River Laboratories International shares outstanding
- Charles River Laboratories International total debt
- Charles River Laboratories International cash on hand
- Charles River Laboratories International total assets
- Charles River Laboratories International return on equity (ROE)
- Charles River Laboratories International return on invested capital (ROIC)
Charles River Laboratories International (CRL) overview: price, valuation and scorecardAll health care companies by market value
Charles River Laboratories International P/E ratio: questions and answers
What is Charles River Laboratories International's P/E ratio?
Charles River Laboratories International (CRL) trades at 361.0× its earnings per share over the last twelve months. At the end of fiscal 2023 (December 31, 2023) its P/E ratio was 25.6×. That is 11.5% higher than the 23.0× of fiscal 2022.
Is Charles River Laboratories International's P/E ratio high or low compared with its own history?
Today's P/E ratio is above every one of the 14 fiscal year-ends on record; their median is 24.8×.
What are the highest and lowest P/E ratio figures on record for Charles River Laboratories International?
Across the 14 fiscal year-ends on record (2009–2023), the highest was 49.6× in fiscal 2021 and the lowest 12.8× in fiscal 2011.
How is Charles River Laboratories International's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Charles River Laboratories International (CRL) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CRL/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.